VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has confirmed in its own preclinical study, that AP-188 (“N,N-Dimethyltryptamine or “DMT”), increased the growth of cortical neurons by 40%


Previous articlePT261 – Dr. Tiago Reis Marques – Ketamine, New Drugs, and the Repurposing of Current Drugs
Next articleGlutamate’s Role in Rapidly-Acting Antidepressants